VVOS Vivos Therapeutics
Vivos Therapeutics earnings company data as of 4:48 AM ET 10/22
History
2 periods, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 18 Nov | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 14 Aug | EPS | — | -0.31 | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by VVOS's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $1.8M bought by 1 insider
- None no sales outside a trading plan
- None no planned (10b5-1) sales
-
Michael C Skaff 10% owner, +1 joint filerBuy$1.8M 1,353,625 shares at $1.34 New stakeTraded Mar 31 Filed Apr 2
Also filed in the last 12 months, not counted as buying or selling: 1 stock grant and 1 other transaction.
SEC filings
Recent issuer filings from EDGAR, 25 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 8.01,9.01 | Filing Doc | |
| 8-K | 1.01,2.01,3.02,3.03,5.03,7.01,8.01,9.01 | Filing Doc | |
| 8-K | 1.01,7.01,8.01,9.01 | Filing Doc | |
| 8-K | 4.01,9.01 | Filing Doc | |
| 8-K/A | 1.01,3.02,9.01 | Filing Doc | |
| 8-K | 1.01,3.02,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc | |
| 8-K | 1.01,5.02,9.01 | Filing Doc | |
| SCHEDULE 13D | — | Filing Doc | |
| 8-K | 1.01,3.02,5.03,9.01 | Filing Doc | |
| 8-K | 1.01,7.01,9.01 | Filing Doc | |
| 8-K | 1.01,7.01,9.01 | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| 8-K | 1.01,2.03,3.01,3.02,7.01,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| 424B3 | Filing Doc | ||
| 8-K | 3.01 | Filing Doc | |
| 10-K | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.